RU99108674A

RU99108674A - NEW HETEROARYLOXYETHYLAMINES, METHOD FOR THEIR PRODUCTION, THEIR USE AS A MEDICINE FACILITY AND CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS

Info

Publication number: RU99108674A
Application number: RU99108674/04A
Authority: RU
Inventors: Дени Бигг; Мари-Одиль ГАЛЬСЕРА
Original assignee: Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик (С.К.Р.А.С.)
Priority date: 1996-09-27
Filing date: 1997-09-26
Publication date: 2001-06-27

Claims

1. Compounds of General Formula I

in which Ar represents a bicyclic heteroaryl, optionally substituted by one or more substituents; Y represents a radical —C (O) NH— or —NHC (O) -; R represents a lower alkyl radical; cycloalkyl, optionally substituted with one or more lower alkyl; or phenyl, optionally substituted with one or more substituents selected from the group consisting of a hydroxyl group, cyano group, halogen, trifluoromethyl, lower alkyl, lower alkoxy radicals; or salts of these compounds.

2. Compounds of general formula I according to claim 1, in which Ar is a bicyclic heteroaryl radical containing one or two nitrogen atoms, and the substituent (s) which (e) may contain an Ar radical, is selected from the group comprising a hydroxyl group, nitro, halogen, lower alkyl, lower alkoxy, lower alkylcarbonyl radicals.

3. Compounds of the general formula I according to claims 1 or 2, in which Ar is a quinolyl or quinoxalinil radical, and the substituent (s), which (e) may contain an Ar radical, is selected from the group comprising a hydroxyl group, chlorine, methyl .

4. Compounds of General formula I in one of the paragraphs.1 to 3, corresponding to the following formulas:
-N- [4 - ({2- (8-quinolyloxy) ethyl} amino) butyl] tert-butanamide,
-N- [4 - ({2- (8-quinolyl) ethyl} amine) butyl] neopentan-amide,
-N- [4 - ({2- (8-quinolyloxy) ethyl} amino) butyl] cyclohexanamide,
-4-methyl-N- [4 - ({2- (8-quinolyloxy) ethyl} amino) butyl] cyclohexanamide,
-N- [4 - ({2- (8-quinolyloxy) ethyl} amino) butyl] benzamide,
-N- [4 - ({2- (8- (5-chloro) quinolyloxy) ethyl} amino) butyl] neopentanamide,
-N- [4 - ({2- (8- (2-methyl) quinolyloxy) ethyl} amino) butyl] neopentanamide,
-N- [4 - ({2- (5-quinolyloxy) ethyl} amino) butyl] benzamide,
-N- [4 - ({2- (5-quinoxalyloxy) ethyl} amino) butyl] benzamide,
-N- [4 - ({2- (8- (2-hydroxy) quinolyloxy) ethyl} amino) butyl] benzamide,
-N-cyclohexyl-5 - [(2- {8-quinolyloxy} ethyl) amino] pentanamide,
-N-neopentyl-5 - [(2- {8-quinolyloxy} ethyl) amino] pentanamide,
-N-neopentyl-5 - [(2 - ({5-quinoxalyloxy} ethyl) amino] pentanamide, or the salts of these compounds with inorganic or organic acids.

5. The method of obtaining compounds of formula I according to claim 1, characterized in that the compound corresponding to formula II

where Y and R are as defined above, and X is halogen or pseudohalogen, interacts with N-benzylethanolamine corresponding to the formula

to obtain compounds corresponding to formula III

which is converted to a compound corresponding to formula IV

where Z is a halogen or pseudohalogen, which is converted into a compound corresponding to the formula V

where Ar takes the above values, and the benzyl fragment of compound V is cleaved to obtain the compound of formula I, and the compound of formula I can be converted into acid salts by reacting with the corresponding acid.

6. The compounds of formula I according to claim 1 and the additive salts of the compounds of formula I with pharmaceutically acceptable inorganic or organic acids, useful as medicines.

7. The compounds of formula I according to any one of paragraphs.2 to 4 and the additive salts of these compounds of formula I with pharmaceutically acceptable inorganic or organic acids useful as drugs.

8. Pharmaceutical compositions containing as active ingredient at least one of the drugs according to claim 6 or 7.

9. Compounds of the general formula I according to any one of claims 1 to 4 are useful for the preparation of anti-emetic drugs.

10. The compounds of general formula I according to any one of claims 1 to 4 are useful for the production of medicaments for reducing gastric secretion.

11. The compounds of general formula I according to any one of claims 1 to 4 are useful for the preparation of medicaments intended to accelerate gastric emptying.

12. Compounds of General formula I according to any one of paragraphs.1 to 4 useful for obtaining drugs intended to modify the passage of contents through the intestine.

13. The compounds of general formula I according to any one of claims 1 to 4 are useful for the preparation of medicaments for treating anxiety, depression, sleep disorders.

14. The compounds of general formula I according to any one of claims 1 to 4 are useful for the preparation of medicaments for the treatment of cardiovascular diseases, in particular hypertension.

15. Compounds of General Formula V

in which Ar represents a bicyclic heteroaryl, optionally substituted by one or more substituents; Y represents a radical —C (O) NH— or —NHC (O) -; R represents a lower alkyl radical; cycloalkyl, optionally substituted by one or more lower alkyl; or phenyl, optionally substituted with one or more substituents selected from the group consisting of a hydroxyl group, cyano group, halogen, trifluoromethyl, lower alkyl, lower alkoxy radicals; as a new industrial compound.